Clinical Trials Browser

Phase 1/2 × NETWORK × 30 days × Clear all

NCT02285816 2026-03-09

MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid Tumours

Phase 1/2 Active not recruiting

56 enrolled

Other solid neoplasm

Advanced/Metastatic Solid Tumours

NCT03504644 2026-02-25

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

40 enrolled 18 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Phase 1/2 Recruiting

147 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

NCT04870944 2026-02-24

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Phase 1/2 Recruiting

63 enrolled

CNSLymphoid

Diffuse Intrinsic Pontine Glioma, Lymphoma

NCT06620302 2026-02-24

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1/2 Recruiting

81 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma